Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)

Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)

In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l. This was done in a large observational study (TARGET) representing daily practice. Primary end points analysis was the percentage of patients reaching the target of LDL-C < 3.2 mmol/l. Secondary outcomes were the changes of LDL-C, HDL-C, TC, Triglycerides (TG) and TC/HDL-C-ratio from baseline.

Inclusion Criteria:

• High-risk patients with and without evident CHD who had LDL-C > 3.2 mmol/l and were treated at that moment with HMG-CoA-reductase inhibitor apart from rosuvastatin.
• Patients were aged >18 years and <70 years (men) and < 75 years (women).

Exclusion Criteria:

• Treatment with atorvastatin 40 or 80 mg or simvastatin 80 mg
• Patients familiar with muscular pain, myopathy or liver function disorders (inclusive elevation of serum transaminases) and/or contra-indications for treatment with rosuvastatin